28.11.2017

MOLOGEN with two posters at ESMO IO 2017

The biopharmaceutical company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) will be represented with two posters at the ESMO IO 2017 (European Society for Medical Oncology – Immuno Oncology) in Geneva, Switzerland (7 – 10 December 2017).

The first poster is featuring data on patient characteristics from the pivotal IMPALA study in metastatic colorectal cancer evaluating the lead product candidate lefitolimod. A second poster will show the impact of the TLR9 agonist EnanDIM® on tumor microenvironment (TME) in murine models.

Abstract details:

1. Abstract number: 271  

Title: “Patient characteristics after completion of recruitment from the phase 3 IMPALA study with lefitolimod in metastatic colorectal carcinoma”

Presentation: The poster viewing session will take place during the lunch on Friday, 8 and Saturday 9 December, 12:30-13:00.

2. Abstract number: 244 

Title: “Modulation of the tumor microenvironment by the TLR9 agonist EnanDIM and combination with checkpoint inhibition for cancer immunotherapy”

Presentation: The poster viewing session will take place during the lunch on Friday, 8 and Saturday 9 December, 12:30-13:00.

Both abstracts will be published in the ESMO Immuno Oncology Congress 2017 Abstract Book, a supplement to the official ESMO journal Annals of Oncology.

For more information on ESMO IO 2017 please visit the website

MOLOGEN AG

MOLOGEN AG is a biopharmaceutical company and considered a pioneer in the field of immunotherapy on account of its unique active agents and technologies. Alongside a focus on immuno-oncology, MOLOGEN develops immunotherapies for the treatment of infectious diseases. 

The immunotherapy lefitolimod (MGN1703) is the company’s lead product and is regarded as the best-in-class TLR9 agonist. Treatment with lefitolimod triggers a broad and strong activation of the immune system. On account of this action mechanism, lefitolimod is an immune surveillance reactivator (ISR) and could potentially be used in various indications. The ISR lefitolimod is currently being developed within the framework of a pivotal study for first line maintenance therapy for colorectal cancer. The phase II IMPULSE study in small cell lung cancer is showing positive results in two previously defined and clinically relevant patient sub-groups, even though the primary endpoint “Overall Survival” in the overall study population was not met in this very challenging indication. Detailed analyses of IMPULSE data and data from the extension phase of the TEACH study in HIV, published in August, are currently being conducted. In addition, lefitolimod is currently being investigated in a phase I combination study with the checkpoint inhibitor ipilimumab (Yervoy®) in various cancer indications. In tandem with various checkpoint inhibitors, lefitolimod, which is being investigated as part of a phase III clinical trial currently, is one of the few near-to-market product candidates in the field of immuno-oncology.  

MOLOGEN’s pipeline focus is on new innovative immunotherapies to treat diseases for which there is a great medical demand in particular. 

www.mologen.com 

Contact

Claudia Nickolaus

Head of Investor Relations & Corporate Communications

Tel: +49 - 30 - 84 17 88 - 38

Fax: +49 - 30 - 84 17 88 - 50

Disclaimer

Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial indicators, developments of the financial situation or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for these forward-looking statements. It is not responsible for updating such information, which only represents the state of affairs on the day of publication.